Capital Increase / Dilution2026-08-11

Listing Date Delayed for Capital Increase

UNI

한국유니온제약

080720

+0.05

Signal Score

50CNeutral
Score50 / 100

Historical Avg Return (5d)

+0.00%

Data Coverage

100%n=2740

Risk-adjusted indicator based on 2740 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEUTRAL

Key Numbers

  • • New Listing Date: 2026.08.28 (originally 2026.08.18)
  • • Initial Filing Date: 2026.05.18
  • • Court Approval Date for Rehabilitation Plan: 2026.05.12
  • • Debt-to-Equity Conversion Effective Date: 2026.05.19

AI Analysis Summary

UNION KOREA PHARM CO.,Ltd announced an amendment to its Material Fact Report regarding a paid-in capital increase. The primary change is the delay of the new shares' listing date from August 18, 2026, to August 28, 2026, due to administrative procedures with the Korea Securities Depository. This capital increase is part of a rehabilitation plan approved by the Seoul Rehabilitation Court on May 12, 2026, involving a debt-to-equity conversion effective May 19, 2026, and a capital reduction effective May 27, 2026. The purpose of the new share issuance is to repay certain rehabilitation claims through debt-to-equity conversion, which is expected to result in a change of the largest shareholder. No new cash payment for shares is involved.

How This Event Is Evaluated

Capital Raise Evaluation

Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Potential dilution rate
  • Issuance or conversion price
  • Funding purpose
  • Shareholder value impact
Read our full scoring methodology →

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: [기재정정]주요사항보고서(유상증자결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.